Volume 19, Number 11—November 2013
Research
CTX-M β-Lactamase–producing Klebsiella pneumoniae in Suburban New York City, New York, USA
Table 3
Selected clinical/epidemiologic features of the 25 patients with CTX-M ESBL–producing K. pneumoniae from New York, USA and certain microbiological characteristics of the isolates*
Year | Isolate | Patient age, y | Sex | Source | ≤72 h of admission | Prior hospital admission† | Prior ESBL KP/E. coli† | LOS, d‡ | Disk diffusion (mm) |
MIC (μg/mL) |
β-lactamase(s) | PFGE type (n = 17) | ST type (n = 18) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTX | CAZ | CTX | CAZ | ||||||||||||
2009 | T76 | 93 | M | Urine | N | Y | N | 11 | 9 | 18 | >256 | 8 | CTX-M-15, SHV-28, TEM-1 | PF5 | 15 |
PK114 | 72 | F | Urine | Y | Y | N | 5 | ND | ND | ND | ND | CTX-M-15, SHV-11, TEM-1 | ND | 437 | |
2010 | KF351 | 24 | M | Urine | N | Y | N | 7 | 8 | 21 | >256 | 3 | CTX-M-2, SHV-11, TEM-1 | PF6 | 792 |
KF403 | 71 | F | Urine | Y | Y | Y/Y | 10 | 6 | 13 | >256 | 32 | CTX-M-15, SHV-11, TEM-1 | PF6 | 437 | |
KF548 | 31 | M | Blood | N | Y | N | 20 | 10 | 15 | >256 | 16 | CTX-M-15, SHV-27, TEM-1 | PF1 | 280 | |
KF563 | 57 | M | Respiratory | N | Y | Y | 20 | 6 | 6 | >256 | 96 | CTX-M-15, SHV-28, TEM-1 | PF2 | 15 | |
KF602 | 70 | M | Urine | N | N | N | 3 | 8 | 14 | 128 | 12 | CTX-M-15, SHV-11, TEM-1 | PF7 | 17 | |
PK6 | 71 | M | Respiratory | N | Y | N/Y | 4 | ND | ND | ND | ND | CTX-M-3, SHV-11, TEM-1 | ND | ND | |
2011 | KG318 | 64 | F | Urine | Y | Y | Y | 8 | 6 | 12 | >256 | 64 | CTX-M-15 | PF8 | ND |
KG291 | 67 | M | Urine | N | N | N | 19 | ND | ND | ND | ND | CTX-M-15, SHV-11, TEM-1 | ND | ND | |
KG304 | 44 | F | Urine | Y | Y | Y | 21 | 6 | 9 | >256 | 32 | CTX-M-15, SHV-1, TEM-1 | PF8 | 252 | |
KP33 | 71 | F | Urine | N | Y | N | 13 | 10 | 17 | >256 | 8 | CTX-M-15, SHV-1, TEM-1 | PF3 | 16 | |
KP38 | 69 | M | Urine | Y | Y | N | 7 | 10 | 19 | >256 | 6 | CTX-M-1, SHV-11 | PF3 | 11 | |
KP34 | 62 | M | Urine | Y | Y | Y | 12 | 13 | 22 | 32 | 3 | CTX-M-15, SHV-11 | PF5 | 147 | |
KP41 | 7 | F | Wound | Y | Y | N | 1 | 6 | 18 | >256 | 12 | CTX-M-15, SHV-1, TEM-1 | PF4 | ND | |
KP35 | 39 | F | Urine | Y | N | N | 1 | 6 | 13 | >256 | 32 | CTX-M-15, SHV-11 | PF5 | 392 | |
KP37 | 44 | M | Blood | Y | Y | N | 5 | 6 | 10 | >256 | 48 | CTX-M-15, SHV-1 | PF4 | 15 | |
PK23 | 15 | M | Respiratory | Y | N | N | 5 | 10 | 18 | 128 | 6 | CTX-M-15, SHV-11, TEM-1 | PF4 | 48 | |
PK30 | 62 | F | Respiratory | N | N | N | 26§ | 9 | 8 | >256 | 16 | CTX-M-3, SHV-11, TEM-1 | PF3 | ND | |
PK107 | 71 | F | Blood | N | N | N | 90§ | 8 | 8 | >256 | >256 | CTX-M-3, SHV-11, TEM-1 | PF3 | 11 | |
2012 | PK133 | 52 | M | Urine | Y | Y | N | 90 | 6 | 15 | 128 | 24 | CTX-M-15, SHV-11 | ND | ND |
PK135 | 81 | F | Urine | N | N | N | 14 | 11 | 20 | 64 | 6 | CTX-M-3, SHV-11, TEM-1 | ND | 11 | |
PK140 | 66 | F | Urine | Y | Y | N/Y | 7 | 7 | 15 | >256 | 16 | CTX-M-15, SHV-11 | ND | 392 | |
CK17 | 34 | F | Urine | Y | N | N | 26 | 16 | 8 | 16 | >256 | CTX-M-15, SHV-12 | ND | 258 | |
CK30 | 53 | M | Wound | N | N | N | 77 | 6 | 15 | >256 | 48 | CTX-M-15, SHV-1, TEM-1 | ND | nd |
*ESBL, extended-spectrum β-lactamase; ; CTX: cefotaxime; CAZ: ceftazidime; PFGE, pulsed-field gel electrophoresis; ST, sequence type; Y, yes; N, noND, not determined.
†Prior hospitalization or history of recovering ESBL K. pneumoniae (KP) and E. coli isolate within 8 mo of the current admission.
‡LOS, length of stay after the recovery of CTX-M K. pneumoniae.
§Patients died.